Edit

Columbus Venture Partners

https://www.columbusvp.com/
Last activity: 04.06.2026
Active
Portfolio
3
Mentions
44
Employees: 11-50
Email

Portfolio 3

DateNameWebsiteTotal RaisedLocation
07.11.2025accipiterbio.com$12.7MUnited Sta...
03.05.2023ARTHEx Bio...arthexbiotech.com$138.32MSpain
30.03.2022Integra Th...integra-tx.com$25.7MSpain

Mentions in press and media 44

DateTitleDescription
04.06.2026Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Deve...Barcelona, Spain, 4 June 2026: Ona Therapeutics (“Ona”), a global biopharmaceutical company pioneering first-in-class antibody-drug conjugates (ADCs) to address treatment-resistant cancers, today announced the closing of an oversubscribed $...
27.05.2026AI firm Visium secures funds to scale across Europe and US Founded in 2018 in Lausanne, Visium provides AI and data services to companies in regulated industries, primarily life sciences and specialty chemicals. The company runs a dual model that combines consulting with software products, includi...
08.11.2025Accipiter Biosciences Secures $12.7M Seed Funding, Revolutionizing Protein TherapiesAccipiter Biosciences, a Seattle biotech, exited stealth with $12.7 million in seed funding. The company pioneers de novo multifunctional protein therapeutics. Its computational platform designs novel biologics from scratch. These single mo...
07.11.2025Accipiter Biosciences Raises $12.7M in Seed FinancingAccipiter Biosciences, a Seattle, WA-based biotechnology company developing de novo multifunctional biologics to treat complex diseases, raised $12.7M in Seed funding. The round was co-led by Takeda and Flying Fish Partners, with participat...
07.11.2025Accipiter Biosciences: $12.7 Million Seed Funding Closed To Develop De Novo Protein TherapiesAccipiter Biosciences has emerged from stealth with $12.7 million in seed funding to advance a new class of de novo multifunctional protein therapeutics designed to treat complex diseases. The seed round was co-led by Takeda and Flying Fish...
26.09.2025Nscale raises $1.1BN Series B, the biggest European energy deals in H1 2025, and inside Antler’s "Day Zero" strategyThis week, we tracked more than 80 tech funding deals worth over €2.2 billion, and over 10 exits, M&A transactions, rumours, and related news stories across Europe. In addition to this week's top financials, we've also indexed the most ...
22.09.2025ARTHEx Biotech: Series B Round Upsized To $87 Million For Myotonic Dystrophy Treatment DevelopmentARTHEx Biotech, a biotechnology company in the clinical stage of development, has recently made a significant announcement regarding its financing efforts. The company focuses on creating targeted RNA medicines, particularly for rare geneti...
16.09.2025Spanish cancer startup Highlight Therapeutics closes €15 million round to further skin tumour treatmentValencia’s Highlight Therapeutics, a biopharmaceutical company focused on the development of next-generation immunotherapies, has raised €15 million aimed at strengthening their position in the treatment of skin tumours and accelerating its...
08.09.2025Integra Therapeutics raises €10.7M to advance FiCAT platform and CAR-T validationBarcelona-based Integra Therapeutics has closed a €10.7 million pre-Series A round to advance its gene writing technologies designed to improve the safety, precision, and efficacy of advanced therapies. Founded in 2020 by Dr. Marc Güell and...
08.09.2025Integra Therapeutics Raises €10.7M in FundingIntegra Therapeutics, a Barcelona, Spain-based gene writing tools provider, raised €10.7M in funding. Backers included IC Fund (European Commission) and CDTI Innvierte (Government of Spain) and current investors (AdBio, Columbus, Invivo and...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In